Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stereotaxis, Inc. Common Stock
(NY:
STXS
)
1.265
-0.065 (-4.89%)
Streaming Delayed Price
Updated: 3:32 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stereotaxis, Inc. Common Stock
< Previous
1
2
3
Next >
Unusual volume stocks in Monday's session
↗
July 20, 2026
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 16, 2026
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased...
Via
Benzinga
Thursday's after hours session: top gainers and losers
↗
July 16, 2026
Via
Chartmill
Stereotaxis Q1 Earnings Call Highlights
↗
May 15, 2026
Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products...
Via
MarketBeat
Topics
Earnings
Stereotaxis Inc (NYSEARCA:STXS) Slides 6% After Q1 Revenue Miss Despite Narrower-Than-Expected Loss
↗
May 12, 2026
Via
Chartmill
STEREOTAXIS INC (NYSEARCA:STXS) Posts Narrower-Than-Expected Q4 Loss Despite Revenue Miss
↗
March 09, 2026
Via
Chartmill
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
Stereotaxis Earnings Preview
↗
November 08, 2024
Via
Benzinga
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
April 06, 2026
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...
Via
MarketMinute
Topics
Artificial Intelligence
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
April 06, 2026
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that...
Via
MarketMinute
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
↗
March 21, 2026
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...
Via
The Motley Fool
Topics
Derivatives
ETFs
Regulatory Compliance
3 Underrated Robotics Stocks Poised for Huge Gains
↗
December 15, 2025
Via
MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
November 12, 2025
Via
Benzinga
STEREOTAXIS INC (NYSEARCA:STXS) Stock Falls 9.5% After Q3 2025 Revenue Miss
↗
November 11, 2025
Stereotaxis stock fell sharply after Q3 2025 results, as a 13% revenue miss overshadowed a smaller-than-expected quarterly loss.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 11, 2025
Via
Benzinga
Earnings Scheduled For November 11, 2025
↗
November 11, 2025
Via
Benzinga
A Look at Stereotaxis's Upcoming Earnings Report
↗
November 10, 2025
Via
Benzinga
New Robotic System Promises Faster, Safer Care For Arrhythmia Patients
↗
September 22, 2025
Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions.
Via
Benzinga
Stereotaxis Inc (NYSEARCA:STXS) Q2 2025 Earnings: Revenue Surpasses Forecasts, Losses Narrower Than Expected
↗
August 07, 2025
Stereotaxis Inc (NYSE:STXS) Q2 2025 earnings beat revenue estimates with $8.8M, narrowing losses to -$0.05 EPS. Stock rose 1.83% post-announcement.
Via
Chartmill
Topics
Earnings
What's Going On With Stereotaxis Shares Wednesday?
↗
March 19, 2025
Stereotaxis shares are moving higher on Wednesday after the company announced it was accepted into the NVIDIA Connect program.
Via
Benzinga
Earnings Scheduled For March 3, 2025
↗
March 03, 2025
Via
Benzinga
Earnings Scheduled For November 11, 2024
↗
November 11, 2024
Via
Benzinga
STXS Stock Earnings: Stereotaxis Misses EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
STXS stock results show that Stereotaxis missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying
↗
June 18, 2024
Via
Benzinga
STXS Stock Earnings: Stereotaxis Meets EPS, Misses Revenue for Q1 2024
↗
May 13, 2024
STXS stock results show that Stereotaxis met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
↗
April 19, 2024
Although penny stocks to rebound represent one of the riskiest market categories, there could be some substance here.
Via
InvestorPlace
7 Penny Stocks That Could 5X by the End of 2024
↗
April 10, 2024
These seven penny stocks to buy have the potential to 5X your money by the end of 2024 if the right catalysts unfold.
Via
InvestorPlace
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
↗
March 17, 2024
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 04, 2024
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
